Bitte wählen Sie:

Universitätsklinikum Essen
Direkteinstieg:
Forschung

Ausgewählte Publikationen

  • Ferdinandus J, Fragoso Costa P, Kessler L, Weber M, Hirmas N, Kostbade K, Bauer S, Schuler M, Ahrens M, Schildhaus HU, Rischpler C, Grafe H, Siveke JT, Herrmann K, Fendler W, Hamacher R. Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. J Nucl Med. 2021 Aug 12:jnumed.121.262468. doi: 10.2967/jnumed.121.262468. Epub ahead of print. PMID: 34385340.
  • Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, Sandhu S, Kratochwil C, Esfandiari R, Tauber R, Zeldin A, Rathke H, Armstrong WR, Robertson A, Thin P, D'Alessandria C, Rettig MB, Delpassand ES, Haberkorn U, Elashoff D, Herrmann K, Czernin J, Hofman MS, Fendler WP, Eiber M. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021 Aug;22(8):1115-1125. doi: 10.1016/S1470-2045(21)00274-6. Epub 2021 Jul 8. PMID: 34246328.
  • Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23. PMID: 34161051; PMCID: PMC8446332.
  • Ga-68-FAPI for sarcoma imaging: Data from the FAPI-PET prospective observational trial
    Lukas Kessler, Rainer Hamacher, Justin Ferdinandus, Fadi Zarrad, Nader Hirmas, Hans-Ulrich Schildhaus, Jens Siveke, Ken Herrmann, Wolfgang Fendler
    Journal of Nuclear Medicine May 2021, 62 (supplement 1) 126.
  • PERCIST-derived metabolic volume response predicts overall and progression-free survival in patients with malignant pleural mesothelioma treated with Pembrolizumab
    Justin Ferdinandus, Francesco Barbato, Michal Chodyla, Wolfgang Fendler, Lukas Kessler, Martin Metzenmacher, Frederik Krefting, Thomas Hager, Ken Herrmann, Daniel Christoph
    Journal of Nuclear Medicine May 2020, 61 (supplement 1) 243;
  • Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, Calais J, Rauscher I, Rathke H, Tauber R, Delpassand ES, Weber WA, Herrmann K, Czernin J, Eiber M, Hofman MS. Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. Eur Urol. 2020 Aug;78(2):148-154. doi: 10.1016/j.eururo.2020.05.004. Epub 2020 Jun 10. PMID: 32532512.
  • Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 Dec 15;25(24):7448-7454. doi: 10.1158/1078-0432.CCR-19-1050. Epub 2019 Sep 11. PMID: 31511295.
  • Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP. 68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. J Urol. 2019 Dec;202(6):1174-1181. doi: 10.1097/JU.0000000000000417. Epub 2019 Jun 24. PMID: 31233369.
  • Dominic Kaddu-Mulindwa, Bettina Altmann, Gerhard Held, Marita Ziepert, Karin Menhart, Jirka Grosse, Stephanie Angel, Stephan Stilgenbauer, Michael Pfreundschuh, Ken Herrmann, Ulrich Duehrsen, Andreas Hüttmann, Francesco Barbato, Dirk Hellwig, Viola Poeschel; Role of FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Aggressive Non-Hodgkin Lymphoma. Blood 2019; 134 (Supplement_1): 2892. doi: https://doi.org/10.1182/blood-2019-128896
  • Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial Investigators. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11. PMID: 29750632.